Alzheimer's disease and blood–brain barrier function—Why have anti-β-amyloid therapies failed to prevent dementia progression?
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Proteopathies of the brain are defined by abnormal, disease-inducing protein deposition that leads to functional abrogation and death of neurons. Immunization trials targeting the removal of amyloid-β plaques in Alzheimer's disease have so far failed to stop the progression of dementia, despite autopsy findings of reduced plaque load. Here, we summarize current knowledge of the relationship between AD pathology and blood-brain barrier function, and propose that the activation of the excretion function of the blood-brain barrier might help to achieve better results in trials targeting the dissolution of cerebral amyloid-β aggregates. We further discuss a possible role of oligomers in limiting the efficacy of immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 4×
“Since lower-n oligomers are already apparent at younger ages, these may be responsible for the earlier functional effects (Lesné et al., 2006) (Fig.”
InfluentialRetractedAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 2×
“According to the ‘‘amyloid hypothesis’’, the accumulation of Ab peptides within the brain of Alzheimer’s patients leads to the hyperphosphorylation of tau proteins and neuronal dysfunction/death, thereby impairing memory and other cognitive functions such as writing and reading (Hardy and Allsop, 1991; Greenberg and M…”
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 3×
“…and Boche, investigations of transgenic mouse models support the finding that the burden of plaques within the brain is a weak predictor of the functional severity of the disease, and is not likely to account primarily for memory deficits and neuronal loss (Boche et al., 2008; Holmes et al., 2008).”
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 2×
“Apolipoprotein E is considered to be involved in the RAGE/LRP1 shuffling mechanism (Shibata et al., 2000), and polymorphisms in apolipoprotein E (ApoE) are known to markedly influence the risk of late-onset AD (Saunders (Saunders et al., 1993; Schmechel et al., 1993; Strittmatter et al., 1993a,b;…”
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“In contrast, an analysis of the impact of immunotherapy on cerebral amyloid angiopathy (CAA) and microvascular lesions showed a significant increase in vascular Ab42 and Ab40 in cortical vessels (Nicoll et al., 2003; Ferrer et al., 2004; Masliah et al., 2005; Boche et al., 2008).”
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363 · cited 2×
“An allelic variant of the apolipoprotein E (ApoE) gene is considered to be a susceptibility or risk factor for AD (Strittmatter et al., 1993a,b).”
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“The clinical phase 2a trial was halted prematurely when 6% of the vaccinated patients developed subacute meningoencephalitis (Orgogozo et al., 2003).”
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 1×
“Strikingly, Ab oligomers of the same size had been found in AD brain samples and were shown to exhibit binding to cultured hippocampal neurons (Gong et al., 2003).”
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 1×
“We have established several extensively backcrossed mouse models using the APPPS1 doubletransgenic AD model (Radde et al., 2006) in concert with different ABC transporter knockout models.”
MethodBlood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882 · cited 1×
“With respect to dementias, there is reasonable evidence that the BBB becomes increasingly permeable with increasing age, in the presence of AD, and especially in the presence of so-called vascular dementia (VD) (Farrall and Wardlaw, 2009).”
Jonker, J. W., Buitelaar, M., Wagenaar, E., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plösch, T., Kuipers, F., Elferink, R. P. J. O., Rosing, H., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202607599 · Cited by 822
Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600948103 · Cited by 701
Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660
Han, X., M. Holtzman, D., W. McKeel, D., Kelley, J., & Morris, J. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00997.x · Cited by 626 · cited 1×
“Since damage to the white matter is a frequent occurrence in AD, the authors suggest that decreased ABCB1 function may cause myelin damage due to a higher Ab load (Han et al., 2002; Song et al., 2004).”
DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563
Lacunar stroke is associated with diffuse blood-brain barrier dysfunction
Wardlaw, J. M., Doubal, F., Armitage, P., Chappell, F., Carpenter, T., Muñoz Maniega, S., Farrall, A., Sudlow, C., Dennis, M., & Dhillon, B. (2009) · Annals of Neurology · doi:10.1002/ana.21549 · Cited by 364 · cited 1×
“MRI analyses detected increased permeability and enlarged perivascular spaces, further supporting the potential importance of interstitial clearance mechanisms in protecting the brain (Wardlaw et al., 2009).”
Clearing amyloid through the blood-brain barrier
Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336
Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia
Sondag, C. M., Dhawan, G., & Combs, C. K. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-1 · Cited by 295 · cited 2×
“small oligomers on the signaling of primary cultured microglia was reported (Sondag et al., 2009).”
Hung, L. W., Ciccotosto, G. D., Giannakis, E., Tew, D. J., Perez, K., Masters, C. L., Cappai, R., Wade, J. D., & Barnham, K. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3916-08.2008 · Cited by 210
Kim, W. S., Rahmanto, A. S., Kamili, A., Rye, K.-A., Guillemin, G. J., Gelissen, I. C., Jessup, W., Hill, A. F., & Garner, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607831200 · Cited by 191 · cited 1×
“Moreover, the transporters ABCA1, ABCA2 and ABCG2 have been suggested to play a role in the pathobiology of AD by their indirect influence on the processing of APP, or via a high chromosomal linkage with known AD loci (Pericak-Vance et al., 2000; Kim et al., 2007).”
Furuno, T., Landi, M.-T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00004 · Cited by 178
Song, S.-K., Kim, J. H., Lin, S.-J., Brendza, R. P., & Holtzman, D. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.003 · Cited by 170
Cited by
Revett, T. J., Baker, G. B., Jhamandas, J., & Kar, S. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110190 · Cited by 292
Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice
Krohn, M., Lange, C., Hofrichter, J., Scheffler, K., Stenzel, J., Steffen, J., Schumacher, T., Brüning, T., Plath, A.-S., Alfen, F., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57867 · Cited by 183
Self-citationLRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier
Pflanzner, T., Janko, M. C., André-Dohmen, B., Reuss, S., Weggen, S., Roebroek, A. J. M., Kuhlmann, C. R. W., & Pietrzik, C. U. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.025 · Cited by 141
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
Metadata
- Authors
- Pahnke, J., Walker, L. C., Scheffler, K., & Krohn, M.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 33
- Issue
- 7
- Pages
- 1099-1108
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2077744779
- Cited by
- 66
- References
- 27
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.